Panel Discussion: Harnessing the Strength of Diversity in Clinical Trials
Josh Mailman
President, NorCal CarciNET Community
This panel on diversity in clinical trials explored the vital role that diverse populations play in advancing medical research and improving health outcomes. Experts discussed the benefits of diverse trials, such as improved drug efficacy across different populations and better safety profiles alongside strategies for overcoming barriers to participation, ensuring inclusive recruitment practices, and fostering trust within underrepresented communities. The session highlighted real-world examples and provided actionable steps to make clinical trials more equitable and representative.
Josh is an internationally recognized advocate for neuroendocrine tumor patients and integrative oncology, nuclear medicine, and molecular imaging. He is the inaugural chairman of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, an Executive Board Member of the Neuroendocrine Tumor Research Foundation (NETRF), and President of NorCal CarciNET Community. Mr. Mailman has an MBA from the Anderson School of Management at UCLA and has been a technology entrepreneur for over 30 years.
Currently, Mr. Mailman also serves as the co-chair of the NCI Patient Advocate Steering Committee and is the sole patient representative to the Nuclear Regulatory Commission's Advisory Board on the Medical Use of Isotopes.